Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 725 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Anti-PD1 Clear all

Conditions: Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions: INCB001158, Pembrolizumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 13
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: PBF-509_80 mg, PBF-509_160 mg, PBF-509_320 mg, PBF-509_640 mg, Combo PBF-509 (160 mg) + PDR001, Combo PBF-509 (320 mg) + PDR001, Combo PBF-509 (640 mg) + PDR001, RP2D (PBF-509+PDR001)_immuno naïve, Experimental: RP2D (PBF-509+PDR001)_immuno treated; Drug
Lead sponsor: Palobiofarma SL; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Adult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm
Interventions: Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Nivolumab, NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL, NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine, Positron Emission Tomography; Biological · Drug · Other + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Interventions: BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel, Topotecan; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Anchorage, Alaska • Los Angeles, California • Clermont, Florida + 15 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Solid Neoplasm
Interventions: Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy; Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer
Interventions: PF-07921585, Sasanlimab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more

Conditions: Selected Advanced Solid Tumors
Interventions: EOS006215, Anticancer agent; Drug
Lead sponsor: iTeos Belgium SA; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Denver, Colorado • Sarasota, Florida

Conditions: Advanced Solid Tumor
Interventions: TU2218, Anti-PD-1 antibody; Drug
Lead sponsor: TiumBio Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Renal Cell Carcinoma, Advanced Melanoma
Interventions: Sitagliptin, Pembrolizumab; Drug
Lead sponsor: Fernando Maciel Barbosa; Other
Eligibility: 18 Years to 99 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: Pembrolizumab, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 15
States / cities: Tucson, Arizona • Tampa, Florida • Weston, Florida + 12 more

Conditions: Clear Cell Renal Carcinoma
Interventions: MK-3475, Bevacizumab; Drug
Lead sponsor: Arkadiusz Z. Dudek, MD; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 5 more

Conditions: Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions: Magrolimab, Pembrolizumab, PET/CT; Drug · Procedure
Lead sponsor: Ranjana Advani; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Stanford, California • Boston, Massachusetts

Conditions: Solid Tumor, Lymphoma
Interventions: Ad-p53; Drug
Lead sponsor: MultiVir, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • Morristown, New Jersey

Conditions: Glioblastoma Multiforme
Interventions: Retifanlimab, Temozolomide, Radiation Therapy; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-small Cell Lung Cancer
Interventions: Trabedersen, Pembrolizumab; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
Interventions: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more

Conditions: Metastatic Non-small Cell Lung Cancer
Interventions: Dupilumab, PD-1/PD-L1 blockade, Anakinra; Drug
Lead sponsor: Thomas Marron; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Squamous Cell
Interventions: VTX-2337, Nivolumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 4 more

Conditions: Thyroid Cancer, Salivary Gland Cancer
Interventions: Pembrolizumab, Docetaxel; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Pembrolizumab; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • Mineola, New York • New York, New York + 2 more

Conditions: Advanced Melanoma
Interventions: Botensilimab, Balstilimab; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Scottsdale, Arizona • Fullerton, California • Santa Monica, California + 4 more

Conditions: Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
Interventions: BNT111, Cemiplimab; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Tucson, Arizona • San Francisco, California • Miami, Florida + 3 more

Conditions: Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma
Interventions: Radiation Therapy, Cetuximab, Chemotherapy, Immunotherapy; Radiation · Drug
Lead sponsor: Loren Mell, MD; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: La Jolla, California

Conditions: Multiple Myeloma
Interventions: PDR001, CJM112, LCL161; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Phoenix, Arizona • Nashville, Tennessee

Search by objective public record fields.

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Sitagliptin With Pembro in RCC and Melanoma

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Dupilumab_Metastatic NSCLC

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

QUantitative Assessment of Swallowing After Radiation (QUASAR)

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma